The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-ClearedIn VitroDiagnostic Multivariate Index Assay of Proteomic Biomarkers
- 1 December 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (12), 2995-2999
- https://doi.org/10.1158/1055-9965.epi-10-0580
Abstract
Background: After more than a decade of biomarker discovery research using advanced genomic and proteomic technologies, very few biomarkers have been translated into clinical diagnostics for patient care. This has become an urgent issue to be addressed because the continuing funding from both the public and private sources are called into question. Methods: We use as an example, OVA1, the first in vitro diagnostic multivariate index assay (IVDMIA) of proteomic biomarkers recently cleared by the US FDA (Food and Drug Administration) to describe our experience through the long road from biomarker discovery, to validation, and finally to multi-institutional trial for regulatory approval by the FDA. Results: We discuss 3 issues that are key bridges in the path of biomarker development to actual clinical diagnostics: 1) to generate sufficient and “portable” evidence in preliminary validation studies to support investment for large-scale validation trials; 2) to carefully and clearly define clinical utility that balances desire for broad applicability and feasibility for completing clinical trials for regulatory approval; and 3) to select/develop assays with analytical performance suitable for clinical deployment. Conclusions: We learned that the road from biomarker discovery, validation, to clinical diagnostics could be long and winding, and often frustrating. However, we also know that, with the right approaches, at the end of the road, there is a rainbow waiting for us. Impact: Provide insights and recommendations for the translation of proteomic biomarkers into clinical diagnostics. Cancer Epidemiol Biomarkers Prev; 19(12); 2995–9. ©2010 AACR.Keywords
This publication has 12 references indexed in Scilit:
- Cancer Biomarkers: Can We Turn Recent Failures into Success?JNCI Journal of the National Cancer Institute, 2010
- Will Cancer Proteomics Suffer from Premature Death?Clinical Proteomics, 2010
- A Recipe for Proteomics Diagnostic Test Development: The OVA1 Test, from Biomarker Discovery to FDA ClearanceClinical Chemistry, 2010
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI Journal of the National Cancer Institute, 2008
- Who should operate on patients with ovarian cancer? An evidence-based reviewGynecologic Oncology, 2005
- Cancer Proteomics: In Pursuit of “True” Biomarker DiscoveryCancer Epidemiology, Biomarkers & Prevention, 2005
- Transthyretin, a Biomarker for Nutritional Status and Ovarian CancerCancer Research, 2005
- Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian CancerCancer Research, 2004
- The Vision for a New Diagnostic ParadigmClinical Chemistry, 2003
- Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?Clinical Chemistry, 2003